Finding. Two next-generation imipridones that turn on the mitochondrial ClpP protease kill PDAC cells at sub-micromolar doses and work better with lurbinectedin, a transcription-blocking minor-groove binder. ONC212 is the stronger single agent and often the better partner. The apoptotic trail is ClpX loss, ATF4, caspase PARP cleavage; the synergistic blot is DR5 up, Bcl-2 and ClpX down. A non-malignant colon epithelial line mostly walks away.
Why this paper matters
PDAC still needs combinations that are not just more gemcitabine. Imipridones are a mitochondrial-protease strategy. Pairing them with an already-approved transcriptional stressor is a rational stack: wreck mitochondrial proteostasis and block the nuclear recovery program.
The brief stays preclinical. Three lines and a synergy score are not a pancreatic cancer therapy.
What they actually measured
72-hour IC50s, HSA synergy, apoptotic and ISR markers, one normal-cell toxicity check, Westerns for the ONC212–lurbinectedin pair.
How to read the score
Low seventies. Clear ClpP mitochondrial hook plus synergy. Confidence is medium. Score 72.
What to do with it
If you follow ClpP drugs, imipridones, or PDAC combinations, pull the synergy matrices and the ClpX/DR5 blots. Do not write an off-label note. The directional implication is that mitochondrial ClpP activation and transcriptional blockade can be more than additive in PDAC cells, with a first-pass selectivity hint.